Kymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader

Reuters
02 Jun
Kymera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced positive results from its Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader medicine. The study demonstrated over 90% mean STAT6 degradation in blood at all doses above 1.5 mg and complete STAT6 degradation in both blood and skin at all multiple ascending doses equal to or greater than 50 mg. KT-621 showed a safety profile similar to placebo, with no serious adverse events reported. The trial's results indicate potential for treating IL-4/IL-13-driven allergic diseases. Kymera plans to begin two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-132760), on June 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10